Author:
Lin Adam Yuh,Lunsford Jessica,Bear Adham Sean,Young Joseph Keith,Eckels Phillip,Luo Laureen,Foster Aaron Edward,Drezek Rebekah Anna
Abstract
Abstract
Nanocarriers have been explored to improve the delivery of tumor antigens to dendritic cells (DCs). Gold nanoparticles are attractive nanocarriers because they are inert, non-toxic, and can be readily endocytosed by DCs. Here, we designed novel gold-based nanovaccines (AuNVs) using a simple self-assembling bottom-up conjugation method to generate high-peptide density delivery and effective immune responses with limited toxicity. AuNVs were synthesized using a self-assembling conjugation method and optimized using DC-to-splenocyte interferon-γ enzyme-linked immunosorbent spot assays. The AuNV design has shown successful peptide conjugation with approximately 90% yield while remaining smaller than 80 nm in diameter. DCs uptake AuNVs with minimal toxicity and are able to process the vaccine peptides on the particles to stimulate cytotoxic T lymphocytes (CTLs). These high-peptide density AuNVs can stimulate CTLs better than free peptides and have great potential as carriers for various vaccine types.
Publisher
Springer Science and Business Media LLC
Subject
Condensed Matter Physics,General Materials Science
Reference31 articles.
1. Schlom J, Arlen PM, Gulley JL: Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007, 13: 3776–3782. 10.1158/1078-0432.CCR-07-0588
2. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10: 909–915. 10.1038/nm1100
3. Pejawar-Gaddy S, Finn OJ: Cancer vaccines: accomplishments and challenges. Crit Rev Oncol Hematol 2008, 67: 93–102. 10.1016/j.critrevonc.2008.02.010
4. Palucka K, Ueno H, Banchereau J: Recent developments in cancer vaccines. J Immunol 2011, 186: 1325–1331. 10.4049/jimmunol.0902539
5. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995, 154: 3961–3968.
Cited by
69 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献